Sato Research
Contact
1015 Walnut Street
1024 Curtis Building
Philadelphia, PA 19107
Research Contact
1015 Walnut Street
1024 Curtis Building
Philadelphia, PA 19107
Highlighted Publications
Anikeeva N, Panteleev S, Mazzanti NW, Terai M, Sato T, Sykulev Y.: Efficient killing of tumor cells by CAR-T cells demands engagement of a larger number of CARs as opposed to TCRs. Journal of Biological Chemistry 2021, 297(3):101033. doi:10.1016/jbc.2021.101033
This study investigated the controlling molecular mechanisms for activating stimulatory peptide-MHC ligand on CAR- or TCR- T cells. Understanding the differences in molecular mechanisms contributes to improving the efficacy of cytolytic responses for targeting immunotherapy.
Ohara M, Saito K, Kageyama K, Terai M, Cheng H, Aplin AE, Sato T.: Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers 2021 4;13(5):1104. Doi:10.3390/cancers13051104
Terai, M., Kageyama, K., Sugase, T., Lam, B.Q., Alexeev, V. and Sato, T. (2021) Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. Curr Protoc, 1, e110.
The mouse models generated from human metastatic uveal melanoma cell lines or patients’ biopsy specimens implanted into the mice liver to represent the similar tumor microenvironment were compared to mouse model with subcutaneous tumor. Drug efficacy was investigated in vitro and using the liver mouse model.
Publications
- A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma
- Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
- Individualised neoantigen cancer vaccine therapy
- Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress
- Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
- IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
- Review of bi-specific therapies in uveal melanoma
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
- Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
- Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
- Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases
- Phase i Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients with Metastatic Uveal Melanoma
- Improved Uveal Melanoma Copy Number Subtypes Including an Ultra–High-Risk Group
- A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
- Prognostic values of G-protein mutations in metastatic uveal melanoma
- Genetic landscape and emerging therapies in uveal melanoma
- The role of hgf/met signaling in metastatic uveal melanoma
- Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
- Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
- Erratum: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma (Clin Cancer Res (2021) 27 (3190–3200) DOI: 10.1158/1078-0432.CCR-20-3363)